Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
...randomized, double-blind phase III trial (ZODIAC). abs
31495. ASCO. 2009.
(2) De Boer, R. et al. Va...a randomized, double-blind phase III trial (ZEAL). abs
31867, ASCO. 2009.
(3) Natale, R. et al. Van...a randomized, double-blind phase III trial (ZEST). abs
31610. ASCO. 2009.
(4) Ferlay, J. et al. GLO...
First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
... The EXIBT Study oversight committee includes both radiation oncologists
and breast surgeons. Members of the oversight committee members
and ACRO with a focus on radiation oncology are: Douglas
Arthur, MD, Virginia Commonwealth University, Frank Vicini, MD, William
Beaumont, David Wazer...
Replidyne Provides Strategic Update
...greed to by the U.S. Food and Drug Administration (FDA), in which four
Phase III clinical trials consisting of one placebo-controlled trial in
each of abs
and AECB and two non-inferiority trials in CAP would be
adequate to submit a new drug application for faropenem covering the three
indications. In Nov...
Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
...with a much less
About Advanced Bio-Surfaces, Inc.
is a privately held company dedicated to the development of
innovative join...06 and 350 implants have been completed. For additional information
at 952.912.5400 or visit the website at
The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
interested in the OrthoGlide implant, abs
is also involved in a clinical
study. This week, d...November 10th. About Advanced Bio-Surfaces, Inc. abs
is a privately held company dedicated to the devel...
February 2006. For additional information contact abs
at 952.912.5400 or
visit the website at http://ww...
Ascenta Therapeutics Highlights Multiple Data Presentations at
Upcoming AACR Annual Meeting
... molecule Smac mimetic compound PhD,
(SM-164) and agonist TRAIL-R Ascenta
(mapatumumab & Therapeutics
lexatumumab). Human Genome